These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 25564052)
1. [Enhanced growth inhibition by combined two pathway inhibitors on K-ras mutated non-small cell lung cancer cells]. Yang Z; Li Z; Feng H; Bian X; Liu Y; Liu Y Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):645-50. PubMed ID: 25564052 [TBL] [Abstract][Full Text] [Related]
2. [Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line]. Li ZW; Yang ZL; Feng HL; Bian XC; Liu YY; Liu YQ Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):330-5. PubMed ID: 24004591 [TBL] [Abstract][Full Text] [Related]
3. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells]. Liu Y; Chen X; Luo Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280 [TBL] [Abstract][Full Text] [Related]
4. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines. Dogan Turacli I; Ozkan AC; Ekmekci A Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998 [TBL] [Abstract][Full Text] [Related]
5. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models. Schrauwen S; Depreeuw J; Coenegrachts L; Hermans E; Lambrechts D; Amant F Gynecol Oncol; 2015 Jul; 138(1):165-73. PubMed ID: 25933683 [TBL] [Abstract][Full Text] [Related]
6. The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells. Zou ZQ; Zhang LN; Wang F; Bellenger J; Shen YZ; Zhang XH Mol Med Rep; 2012 Feb; 5(2):503-8. PubMed ID: 22101421 [TBL] [Abstract][Full Text] [Related]
7. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization. Kuger S; Flentje M; Djuzenova CS Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922 [TBL] [Abstract][Full Text] [Related]
8. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604 [TBL] [Abstract][Full Text] [Related]
9. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Guenther MK; Graab U; Fulda S Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925 [TBL] [Abstract][Full Text] [Related]
10. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. Meng J; Dai B; Fang B; Bekele BN; Bornmann WG; Sun D; Peng Z; Herbst RS; Papadimitrakopoulou V; Minna JD; Peyton M; Roth JA PLoS One; 2010 Nov; 5(11):e14124. PubMed ID: 21124782 [TBL] [Abstract][Full Text] [Related]
11. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC. Heavey S; Cuffe S; Finn S; Young V; Ryan R; Nicholson S; Leonard N; McVeigh N; Barr M; O'Byrne K; Gately K Oncotarget; 2016 Nov; 7(48):79526-79543. PubMed ID: 27765909 [TBL] [Abstract][Full Text] [Related]
12. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression. Xia A; Li H; Li R; Lu L; Wu X Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933 [TBL] [Abstract][Full Text] [Related]
13. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer. Toulany M; Iida M; Keinath S; Iyi FF; Mueck K; Fehrenbacher B; Mansour WY; Schaller M; Wheeler DL; Rodemann HP Oncotarget; 2016 Jul; 7(28):43746-43761. PubMed ID: 27248324 [TBL] [Abstract][Full Text] [Related]
14. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment]. Zhang YX; Kong CZ Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842 [TBL] [Abstract][Full Text] [Related]
15. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway. Shi H; Pu J; Zhou XL; Ning YY; Bai C Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375 [TBL] [Abstract][Full Text] [Related]
16. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma. Peng X; Liu Y; Zhu S; Peng X; Li H; Jiao W; Lin P; Zhang Z; Qiu Y; Jin M; Wang R; Kong D J Cancer Res Clin Oncol; 2019 Dec; 145(12):2921-2936. PubMed ID: 31620898 [TBL] [Abstract][Full Text] [Related]
17. Tanshinone IIA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way. Xie J; Liu JH; Liu H; Liao XZ; Chen Y; Lin MG; Gu YY; Liu TL; Wang DM; Ge H; Mo SL BMC Cancer; 2016 Nov; 16(1):899. PubMed ID: 27863471 [TBL] [Abstract][Full Text] [Related]
18. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway]. Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997 [TBL] [Abstract][Full Text] [Related]
19. Luteoloside induces G Zhou M; Shen S; Zhao X; Gong X Biochem Biophys Res Commun; 2017 Dec; 494(1-2):263-269. PubMed ID: 29024631 [TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]